Evidence map›Paper›PMID 25199023›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2014

Differences in EBA in the first two days of standard anti-tuberculosis treatment in different geographic regions.

Charles M Bark, Phineas Gitta, John L Johnson

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Clinically encountered growth phenotypes of tuberculosis-causing bacilli and theirFrontiers in cellular and infection microbiology · 2022
    Review
  3. Clinical evaluation of tuberculosis viability microscopy for assessing treatment response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Charles M BarkTuberculosis Research Unit, Case Western Reserve University, Cleveland, OH, USA.
Phineas GittaUganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.
John L JohnsonTuberculosis Research Unit, Case Western Reserve University, Cleveland, OH, USA.

Funding

Clinical and Translational Science Collaborative of ClevelandKL2TR000440 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$11.1M
Tuberculosis Prevention Research Unit /TBRU/-266095383N01AI095383 · NIAID · CASE WESTERN RESERVE UNIVERSITY · 2000 to 2005
$5.6M
NCATS NIH HHS KL2 TR000440NCATS NIH HHS KL2TR000440NIAID NIH HHS HHSN266200700022C/NO1-AI-70022NIAID NIH HHS N01 AI070022NIAID NIH HHS N01 AI095383NIAID NIH HHS N01-AI95383
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Colony Count, MicrobialAntitubercular AgentsDrug MonitoringFemaleHumansMaleMycobacterium tuberculosisTuberculosis, PulmonaryAntitubercular Agents

Identifiers

PMID25199023
PMCPMC4415604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.